Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy

被引：0

作者：

Manso, L. ^{[1
]}

Ciruelos, E. ^{[1
]}

Codes, M. ^{[2
]}

De la Haba, J. ^{[3
]}

Galan, A. ^{[4
]}

Baena, J. ^{[5
]}

Jaen, A. ^{[6
]}

Gil, M. ^{[7
]}

Murias, A. ^{[8
]}

Blancas, I. ^{[9
]}

Gonzalez, E. ^{[10
]}

Perez, D. ^{[11
]}

Bayo, J. L. ^{[12
]}

Mel, J. ^{[13
]}

Garcia-Martinez, E. ^{[14
]}

Cubedo, R. ^{[15
]}

Salvador, J. ^{[16
]}

机构：

[1] Hosp 12 Octubre, E-28041 Madrid, Spain

[2] Hosp Virgen Macarena, Seville, Spain

[3] Hosp Reina Sofia, Cordoba, Spain

[4] Hosp Sagunto, Valencia, Spain

[5] Hosp Puerta Mar, Cadiz, Spain

[6] Hosp Jaen, Jaen, Spain

[7] ICO, Bellvitge, Spain

[8] Hosp Insular, Las Palmas Gran Canaria, Spain

[9] Hosp San Cecilio, Granada, Spain

[10] Hosp Virgen Nieves, Granada, Spain

[11] Hosp Costa Sol, Marbella, Spain

[12] Hosp Juan Ramon Jimenez, Huelva, Spain

[13] Hosp Xeral Calde, Lugo, Spain

[14] Hosp Morales Messeguer, Murcia, Spain

[15] Hosp Puerta Hierro, Madrid, Spain

[16] Hosp Univ Valme, Seville, Spain

来源：

BREAST CANCER RESEARCH | 2011年 / 13卷

关键词：

Breast Cancer; Paclitaxel; Bevacizumab; Gemcitabine; Metastatic Breast Cancer;

D O I：

10.1186/bcr3025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2